DXR
DAXOR CORP
Overview
Daxor Corporation manufactures the BVA-100 Blood Volume Analyzer, a medical device that measures human blood volume in 60-90 minutes for diagnosing and treating heart failure, kidney failure, hypertension, and other conditions.
DAXOR CORP is a Healthcare company operating in Medical Instruments & Supplies with a $55.5M market cap.
Most recent reported earnings: Q2 FY2025 (Aug 28, 2025).
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20252025-08-28EPS$-0.07 vs $0.00—Rev$18.3K vs ——EODHD
- Q1 FY20252025-05-12EPS$0.00 vs $0.00—Rev— vs ——EODHD
- Q4 FY20242025-03-02EPS$0.43 vs $0.00—Rev$695.3K vs ——EODHD
- Q3 FY20242024-11-28EPS$0.00 vs $0.00—Rev— vs ——EODHD
- Q2 FY20242024-08-21EPS$0.00 vs $0.00—Rev$71.8K vs ——EODHD
- Q1 FY20242024-05-15EPS$0.00 vs $0.00—Rev$35.9K vs ——EODHD
- Q4 FY20232024-03-17EPS$0.00 vs $0.00—Rev$82.4K vs ——EODHD
- Q3 FY20232023-11-08EPS$0.00 vs $0.00—Rev$41.2K vs ——EODHD
- Q2 FY20232023-08-27EPS$0.00 vs $0.00—Rev$81.0K vs ——EODHD
- Q1 FY20232023-05-08EPS$0.00 vs $0.00—Rev$40.5K vs ——EODHD
- Q4 FY20222023-02-28EPS$1.54 vs $0.00—Rev$96.4K vs ——EODHD
- Q3 FY20222022-11-09EPS$0.00 vs $0.00—Rev$48.2K vs ——EODHD
- Q2 FY20222022-08-24EPS$-0.45 vs $0.00—Rev$135.2K vs ——EODHD
- Q1 FY20222022-05-14EPS$0.00 vs $0.00—Rev— vs ——EODHD
- Q4 FY20212022-02-14EPS$1.56 vs $0.00—Rev$152.4K vs ——EODHD
- Q3 FY20212021-11-14EPS$0.00 vs $0.00—Rev— vs ——EODHD
- Q2 FY20212021-08-14EPS$-0.38 vs $0.00—Rev$125.7K vs ——EODHD
- Q1 FY20212021-05-14EPS$-0.19 vs $0.00—Rev— vs ——EODHD
- Q4 FY20202021-02-14EPS$0.46 vs $0.04+100.0%Rev$145.5K vs ——EODHD
- Q3 FY20202020-11-14EPS$0.23 vs $0.04+100.0%Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2025 | 2025-08-28 | $-0.07 | $0.00 | — | $18.3K | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $0.00 | $0.00 | — | — | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $0.43 | $0.00 | — | $695.3K | — | — | EODHD |
| Q3 FY2024 | 2024-11-28 | $0.00 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2024 | 2024-08-21 | $0.00 | $0.00 | — | $71.8K | — | — | EODHD |
| Q1 FY2024 | 2024-05-15 | $0.00 | $0.00 | — | $35.9K | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $0.00 | $0.00 | — | $82.4K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $0.00 | $0.00 | — | $41.2K | — | — | EODHD |
| Q2 FY2023 | 2023-08-27 | $0.00 | $0.00 | — | $81.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $0.00 | $0.00 | — | $40.5K | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $1.54 | $0.00 | — | $96.4K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $0.00 | $0.00 | — | $48.2K | — | — | EODHD |
| Q2 FY2022 | 2022-08-24 | $-0.45 | $0.00 | — | $135.2K | — | — | EODHD |
| Q1 FY2022 | 2022-05-14 | $0.00 | $0.00 | — | — | — | — | EODHD |
| Q4 FY2021 | 2022-02-14 | $1.56 | $0.00 | — | $152.4K | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $0.00 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2021 | 2021-08-14 | $-0.38 | $0.00 | — | $125.7K | — | — | EODHD |
| Q1 FY2021 | 2021-05-14 | $-0.19 | $0.00 | — | — | — | — | EODHD |
| Q4 FY2020 | 2021-02-14 | $0.46 | $0.04 | +100.0% | $145.5K | — | — | EODHD |
| Q3 FY2020 | 2020-11-14 | $0.23 | $0.04 | +100.0% | — | — | — | EODHD |
Source: EODHD. DXR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks DXR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $3.57 | $3.15 | +13.3% | +0.5% | +0.1% |
| Q4 FY2024 | $3.48 | $3.10 | +12.4% | +5.3% | +8.3% |
| Q3 FY2024 | $3.62 | $3.25 | +11.3% | -5.0% | -4.4% |
| Q2 FY2024 | $3.41 | $3.21 | +6.1% | +5.9% | +8.1% |
| Q1 FY2023 | $3.34 | $3.17 | +5.4% | -1.0% | -1.5% |
| Q4 FY2023 | $3.72 | $3.37 | +10.4% | -3.4% | -2.8% |
| Q3 FY2023 | $3.76 | $3.15 | +19.5% | -2.8% | -0.6% |
| Q2 FY2023 | $3.62 | $3.33 | +8.6% | +0.4% | -0.3% |
| Q1 FY2022 | $3.56 | $3.24 | +10.0% | +0.8% | +0.1% |
| Q4 FY2022 | $3.96 | $3.36 | +17.9% | -0.9% | -2.4% |
Guidance change history
Sample- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Michael Richard FeldschuhCEO2 yr 6 mono recorded callsCurrentSample
CEO since 2023 • 2/4 beats (50%) • last call held guidance Q2 FY2024
- Robert J MichelCFO2 yr 11 mo4 callsCurrentSample
CFO since 2023 • 2/4 beats (50%) • last call held guidance Q3 FY2024
- John JefferiesChief Medical Officer9 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q3 FY2024
- Jonathan Adam FeldschuhChief Scientific Officer1 yr 6 mono recorded callsCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last call held guidance Q3 FY2024
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for DXR.
$ curl https://api.spokenalpha.com/v1/companies/DXRFAQ
Frequently asked about DXR
Where can I find DAXOR CORP's (DXR) earnings call transcripts?
Spoken Alpha indexes DXR's earnings call transcripts at https://spokenalpha.com/companies/DXR. Each call links to attributed speakers and parsed analyst Q&A. DAXOR CORP's own investor relations page is at https://daxor.com/investors/.
When was DAXOR CORP's most recent earnings call?
DAXOR CORP (DXR) held its most recent earnings call on 2025-03-06, covering fiscal Q4 2024.
What sector is DXR in?
DAXOR CORP (DXR) operates in the Healthcare sector (Medical Instruments & Supplies industry).